Tokyo, Japan

Kazutoshi Yanagibashi


Average Co-Inventor Count = 5.6

ph-index = 2

Forward Citations = 21(Granted Patents)


Company Filing History:


Years Active: 1995-2001

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Kazutoshi Yanagibashi: Pioneering cGMP-PDE Inhibitory Derivatives

Introduction: Kazutoshi Yanagibashi is a notable inventor based in Tokyo, Japan, recognized for his contributions to pharmaceutical innovations. With a total of three patents to his name, his work focuses on developing novel compounds that serve critical therapeutic functions.

Latest Patents: Yanagibashi’s latest inventions include pyridocarbazole derivatives that exhibit selective inhibition of cyclic GMP-phosphodiesterase (cGMP-PDE). This particular invention is groundbreaking as it includes processes for producing such derivatives, as well as agents formulated with these compounds aimed at preventing and treating pulmonary hypertension, ischemic heart diseases, and various other conditions where cGMP-PDE inhibition is beneficial. The novelty of these pyridocarbazole derivatives lies in their highly selective action, enhancing the potential for targeted therapeutic applications.

Career Highlights: Kazutoshi Yanagibashi is affiliated with Mochida Pharmaceutical Co., Ltd., where he has significantly advanced the field of pharmacology through his innovative research and development efforts. His focus on cGMP-PDE inhibitors marks an important step in addressing serious cardiovascular diseases, making his inventions crucial in modern medicine.

Collaborations: Throughout his career, Yanagibashi has worked alongside esteemed colleagues, including Masayuki Ohashi and Toshiyuki Shudo. Their collective expertise fosters an environment of innovation, further enhancing the quality and impact of their research endeavors.

Conclusion: Kazutoshi Yanagibashi continues to be an influential figure in the world of pharmaceutical inventions, particularly through his work on pyridocarbazole derivatives. With his innovative approaches to cGMP-PDE inhibition, he is poised to make a lasting impact on therapeutic treatments for critical health conditions. His ongoing contributions underline the importance of collaboration and ingenuity in the pursuit of scientific advancement.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…